Fishpond Gift Vouchers - Let them choose!

We won't be beaten by anyone. Guaranteed

Therapeutic Antibody Engineering


Product Description
Product Details

Table of Contents

List of figures List of tables List of acronyms, abbreviations, and definitions Foreword Preface About the authors Chapter 1: Introduction to biologics and monoclonal antibodies Abstract: 1.1 Introduction 1.2 Definitions of biologies 1.3 Recombinant protein therapeutics 1.4 MAbs and Fc fusion proteins (FcFPs) 1.5 General anatomy of a therapeutic IgG MAb 1.6 Naming convention for antibodies from different sources Chapter 2: Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins Abstract: 2.1 Overview of discovery and development of therapeutic MAbs and FcFPs 2.2 Market for MAbs and FcFPs 2.3 Currently and recently approved MAbs and FcFPs Chapter 3: Antibody structureaEURO"function relationships Abstract: 3.1 Introduction 3.2 Constant region structure/function 3.3 FAb structure/function Chapter 4: Fundamental technologies for antibody engineering Abstract: 4.1 Introduction 4.2 Hybridoma technology - the gateway for therapeutic monoclonal antibodies 4.3 Key recombinant DNA technologies 4.4 Generation of chimeric antibodies 4.5 Display technologies 4.6 Maturity timelines for biologies technologies Chapter 5: Sources of antibody variable chains Abstract: 5.1 Human antibody gene organization 5.2 Antibody gene rearrangement and diversity in vivo 5.3 Sources of antibody diversity 5.4 Class-switch recombination 5.5 Human variable gene usage 5.6 Variable region selection 5.7 Variable genes from non-human species 5.8 Use of variable genes from humans Chapter 6: Variable chain engineering aEURO" humanization and optimization approaches Abstract: 6.1 Introduction 6.2 Chimerization 6.3 Humanization 6.4 Affinity optimization Chapter 7: Antibody interactions with the immune system Abstract: 7.1 Introduction 7.2 Human Fc receptors 7.3 FcRn and its effect on MAb and FcFP half-life 7.4 Other Fc receptors of importance 7.5 Complement activation Chapter 8: Monoclonal antibody targets and mechanisms of action Abstract: 8.1 Properties of antibody targets 8.2 Antibody mechanisms of action 8.3 CD20 - example of a target for which multiple MOAs apply Chapter 9: Therapeutic antibody classes Abstract: 9.1 Human antibody overview 9.2 Human IgG isotypes 9.3 IgM 9.4 IgA Chapter 10: Antibody Fc engineering for optimal antibody performance Abstract: 10.1 Antibody engineering for decreased or increased effector function 10.2 Current marketed MAbs and clinical candidates with modified Fc 10.3 The effect of human Fc polymorphisms on disease and therapeutic index 10.4 Fc engineering of IgGs to increase effector function 10.5 Fc engineering for silenced effector function 10.6 Fc RIIb-dependent suppression of immune response 10.7 Antibody engineering for modulation of pharmacokinetics 10.8 Tissue targeting Chapter 11: IgG glycans and glyco-engineering Abstract: 11.1 Introduction to Fc glycosylation 11.2 Non-glycosylated IgGs for lowered effector function 11.3 Low- or non-fucosylated oligosaccharides result in higher ADCC 11.4 Non-sialylated IgG glycans result in increased ADCC 11.5 Sialylated IgG glycans may result in immunosuppressive effects 11.6 High-mannose glycoforms 11.7 FAb glycosylation Chapter 12: Antibody fragments as therapeutics Abstract: 12.1 Introduction to antibody fragments and alternative formats 12.2 FAb and scFv antibody fragments 12.3 Domain antibodies, including nanobodies, IgNARs, and nanoantibodies 12.4 Antibody size and tissue distribution 12.5 Strategies for half-life extension of antibody fragments 12.5.2 PEGylation Chapter 13: Multiple antibody and multi-specificity approaches Abstract: 13.1 Introduction 13.2 Serum therapy 13.3 IVIG 13.4 Multi-antibody approaches 13.5 Bispecific antibodies based on IgGs 13.6 Bispecific antibody fragments Chapter 14: FcFPs and similar constructs using Fc Abstract: 14.1 Introduction 14.2 Receptor-FcFPs 14.3 Traps: multi-ligand binding domains of different receptor chains fused to Fc region 14.4 Soluble protein FcFPs 14.5 Antibody fragment - Fc fusion proteins 14.6 Fc peptide fusions as receptor agonist therapeutics 14.7 Other FcFP structures 14.8 Issues to consider with FcFPs Chapter 15: Antibody-drug conjugates Abstract: 15.1 Introduction to antibody-drug conjugates 15.2 Overview and anatomy of a typical ADC 15.3 ADC antibodies and targets 15.4 ADC chemical "warheads" 15.5 ADC linkers 15.6 Issues, limitations, and design of ADCs 15.7 Radioimmunoconjugates 15.8 Protein immunotoxins 15.9 ADEPT 15.10 Other ADC-like approaches Chapter 16: Development issues: antibody stability, developability, immunogenicity, and comparability Abstract: 16.1 Introduction 16.2 Aggregation 16.3 Lack of desired solubility 16.4 Fragmentation 16.5 Post-translational amino acid residue modifications 16.6 Instability and isomerization of disulfide bonds 16.7 Stability at low pH 16.8 Glycosylation issues 16.9 Immunogenicity 16.10 Biocomparability Chapter 17: Interactions of human IgGs with non-human systems Abstract: 17.1 Introduction 17.2 Non-human primate IgGs and Fc receptors 17.3 Mouse IgGs and Fc receptors Chapter 18: Cell line development Abstract: 18.1 Introduction 18.2 Process summary 18.3 Key issues in cell line development 18.4 Choice of cell line 18.5 Mammalian cell lines 18.6 Microbial cells 18.7 Multiple cell lines in single batches 18.8 Gene and vector optimization and selectable markers 18.9 Other industry trends Chapter 19: Issues facing therapeutic monoclonal antibodiesfor the future Abstract: 19.1 Introduction to the future state 19.2 Commoditization of the core underlying technologies 19.3 Impact of follow-on MAbs and FcFPs 19.4 Competition 19.5 The continued need for, and limitation of, novel pre-clinically validated targets 19.6 Payor pressure 19.7 Pipeline in a product concept 19.8 Companion diagnostics and patient segmentation 19.9 Treatment with multiple antibodies and bispecific antibodies 19.10 MAb and FcFP conjugates 19.11 Biopharma in 2020 - the focus on BRIC 19.12 SWOT analysis of therapeutic MAbs and FcFPs 19.13 Epilogue Useful public websites related to antibody engineering References Index

About the Author

Dr William R. Strohl is Vice President of Biologics Research at Janssen R&D Biotechnology Center of Excellence, and was previously a leader in Merck's efforts to discover therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. He has over 100 publications and several patents to his credit, and has edited two books.


An excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learing., mAbs Journal An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's Reviews

Ask a Question About this Product More...
Write your question below:
Look for similar items by category
Home » Books » Science » Biology » Biochemistry
Home » Books » Science » Medical » Immunology
Home » Books » Science » Medical » Biotechnology
People also searched for
How Fishpond Works
Fishpond works with suppliers all over the world to bring you a huge selection of products, really great prices, and delivery included on over 25 million products that we sell. We do our best every day to make Fishpond an awesome place for customers to shop and get what they want — all at the best prices online.
Webmasters, Bloggers & Website Owners
You can earn a 5% commission by selling Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing Series in Biomedicine) on your website. It's easy to get started - we will give you example code. After you're set-up, your website can earn you money while you work, play or even sleep! You should start right now!
Authors / Publishers
Are you the Author or Publisher of a book? Or the manufacturer of one of the millions of products that we sell. You can improve sales and grow your revenue by submitting additional information on this title. The better the information we have about a product, the more we will sell!
Item ships from and is sold by Fishpond World Ltd.
Back to top